Tickwind
TodayOpportunitiesMarketsAI Chat
EN
Log inSign up
Tickwind

Read every tick. See where the market's blowing.

  • X
  • TelegramChinese
  • Newsletter

Product

  • Markets
  • Theme Zones
  • All stocks
  • Compare
  • Hot stocks
  • Opportunities
  • News
  • Discussion
  • Watchlist
  • What's new

Account

  • Settings
  • Newsletter
  • For writers
  • MCP server
  • Contact
  • Log in
  • Sign up
MarketsTheme ZonesAll stocksCompareHot stocksOpportunitiesNewsDiscussionWatchlistWhat's newSettingsNewsletterFor writersMCP serverContactLog inSign up

© 2026 Tickwind. Not investment advice.

Made for the curious investor.

Home/HTGC/Filing changes

HTGC — what changed in the latest 10-Q

A section-by-section comparison of HTGC's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.

Comparing 10-Q · 2026-10-29 vs the prior 10-Q · 2026-07-30

SectionOutcomeAddedRemovedMinorUnchanged
MD&AText added/removed+15−12~7273
Market risk (Item 3)Text added/removed+3−1~22
Controls & proceduresNo paragraph-level changes0002
Legal proceedingsText added/removed00~12
Risk factorsText added/removed+2−1~18
Other informationText added/removed00~10

Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.

Representative excerpts

Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.

MD&A

Text added vs the prior filing · source: 10-Q · 2026-10-29

  • (1)Effective September 30, 2026, the Company added the “Cybersecurity”, “Energy Technologies”, “Financial Technologies” and “Healthcare Technology & Digital Health” industry categories, which include investments previously classified within “Application Software”, “Consumer & Business Services”, “He…
  • (2)See “Note 4 – Investments” for complete list of industry sectors and corresponding amounts of investments at fair value as a percentage of the total portfolio. As of September 30, 2026, the fair value as a percentage of total portfolio does not exceed 5.0% for any individual industry sector other…
  • During the three and nine months ended September 30, 2026, we recognized a net realized loss of $1.9 million and a net realized gain of $5.2 million, respectively. The net realized gains (losses) were generated from gross realized gains of $8.2 million and $18.5 million, respectively, primarily attr…
  • During the three months ended September 30, 2026 and 2025, we recorded approximately $8.2 million of net unrealized appreciation and $33.0 million of net unrealized appreciation, respectively, on our investments. During the nine months ended September 30, 2026 and 2025, we recorded approximately $7.…
  • months ended September 30, 2026 was primarily attributable to foreign exchange movements, including the reversal of previously recorded unrealized depreciation upon repayment of our Euro-denominated credit facility, while valuation changes on our portfolio investments were largely offset by reversal…

Text removed vs the prior filing · source: 10-Q · 2026-07-30

  • (1)See “Note 4 – Investments” for complete list of industry sectors and corresponding amounts of investments at fair value as a percentage of the total portfolio. As of June 30, 2026, the fair value as a percentage of total portfolio does not exceed 5.0% for any individual industry sector other than…
  • During the three and six months ended June 30, 2026, we recognized a net realized gain of $7.7 million and $7.1 million, respectively. The net realized gains (losses) were generated from gross realized gains of $8.7 million and $10.3 million, respectively, primarily attributable to the sale of our e…
  • During the three months ended June 30, 2026 and 2025, we recorded approximately $29.6 million of net unrealized appreciation and $47.8 million of net unrealized appreciation, respectively, on our investments. During the six months ended June 30, 2026 and 2025, we recorded approximately $15.4 million…
  • June 30, 2026 was primarily driven by market recovery across the equity and warrant portfolio and credit spread tightening on the debt portfolio.
  • As of June 30, 2026, our net assets totaled $2.3 billion, with a NAV per share of $12.15. We intend to continue to operate in order to generate cash flows from operations, including income earned from investments in our portfolio companies. Our primary use of funds will be investments in portfolio c…

Market risk (Item 3)

Text added vs the prior filing · source: 10-Q · 2026-10-29

  • (1)Includes change in bank interest income, calculated using the weighted average balance of cash and cash equivalents for the three months ended September 30, 2026.
  • (2)Calculated using the weighted average principal outstanding under the Company’s floating rate Credit Facilities for the three months ended September 30, 2026.
  • From time-to-time, we may hedge against interest rate fluctuations and foreign currency by using standard hedging instruments such as futures, options, and forward contracts. While hedging activities may insulate us against changes in interest rates and foreign currency, they may also limit our abil…

Text removed vs the prior filing · source: 10-Q · 2026-07-30

  • From time-to-time, we may hedge against interest rate fluctuations and foreign currency by using standard hedging instruments such as futures, options, and forward contracts. While hedging activities may insulate us against changes in interest rates and foreign currency, they may also limit our abil…

Risk factors

Text added vs the prior filing · source: 10-Q · 2026-10-29

  • •Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.
  • •Saronic Technologies, Inc. is a defense technology company that designs and builds autonomous surface vessels for maritime defense operations.

Text removed vs the prior filing · source: 10-Q · 2026-07-30

  • •Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.

How to read Risk Factors (Item 1A) in a 10-Q

A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:

  • Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
  • Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
  • Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.

This describes the filing structure only — it is never a judgement on whether risk went up or down.

Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice

More on HTGC

HTGC overviewHTGC quant ratingHTGC fair value (DCF)HTGC vs peersHTGC revenue historyHTGC AI deep research